Bromfenac ophthalmic - InSite Vision

Drug Profile

Bromfenac ophthalmic - InSite Vision

Alternative Names: Bromfenac ophthalmic 0.075%; BromSite; ISV-101; ISV-303

Latest Information Update: 12 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator InSite Vision; Sun Pharmaceutical Industries
  • Class Analgesics; Benzophenones; Bromobenzenes; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Ocular inflammation; Ocular pain
  • Phase I/II Dry eyes
  • Research Retinal oedema

Most Recent Events

  • 08 Sep 2017 InSite Vision plans a phase II trial of bromfenac ophthalmic for Dry eye disease in 2018 (NCT01478555)
  • 28 Aug 2017 InSite Vision withdraws phase II trial of bromfenac ophthalmic for Dry eye disease prior to enrolment (project postponed) (NCT01478555)
  • 28 Nov 2016 Launched for Ocular inflammation in USA (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top